摘要
目的:对肺癌患者支气管肺泡灌洗液(BALF)进行细胞学检查及CYFRA21-1水平的测定,旨在探讨其对肺癌的诊断价值。方法:采用免疫放射分析法(IRMA)测定患者BALF及血清中CYFRA21-1水平及细胞学检查,与纤维支气管镜活检、刷检做比较,评价其对肺癌的诊断价值。结果:1)CYFRA21-1水平肺癌组BALF及血清均高于对照组(P<0.05,<0.01)。2)BALF中CYFR21-1在Ⅰ～Ⅱ期肺癌的阳性率、符合率(75.0%,83.3%)均显著高于血清(6.3%,50.0%)(P<0.01,<0.05)。3)周围型肺癌BALF中CYFRA21-1阳性率(77.3%)及细胞学阳性率(72.7%)显著高于支气管镜活检阳性率(9.1%,P<0.01)及刷检阳性率(36.4%,P<0.05)。结论:检测BALF中肿瘤标志物(TMS)对肺癌早期诊断优于血清;周围型肺癌BALF中CYFRA21-1阳性率及细胞学阳性率显著高于支气管活检和刷检阳性率,是诊断周围型肺癌有效的辅助方法。
Objective: We measured the concentration of CYFRA21-1 and cancer cells in Bronchoalveolar Lavage Fluid(BALF) and serum to evaluate the diagnostic value in lung cancer. Methods: CYFRA21-1 levels were measured with Immunoradiometricassay(IRMA) in the BALF and serum. The diagnostic value of this method in lung cancer was compared with fiberoptic bronchoscopic biopsy and brushing. Results: 1) The levels of CYFRA21-1 in BALF and serum for patients with lung cancer was significant higher than that in benign pulmonary disease patients (P<0.05, P<0.01). 2) CYFRA21-1 in BALF, the sensitivity(75.0%) and accuracy (83.3%) of Stages Ⅰ and Ⅱ in BALF were significant higher than that in serum(6.3%, 50.0%)(P<0.01, P<0.05). 3) The positive rate for CYFRA21-1 and cancer cells in BALF of peripheral lung cancer was 77.3% and 72.7%, significantly higher than that of biopsy(9.1%) or brushing (36.4%) (P<0.05). Conclusions: BALF was more ideal biologic medium than serum for diagnosing lung cancer in the early stages. The positive rate for CYFRA21-1 and cancer cells in BALF of peripheral lung cancer was significantly higher than that of biopsy or brushing. This may be a valuable adjunctive method in the diagnosis for peripheral lung cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2004年第14期808-810,共3页
Chinese Journal of Clinical Oncology
